Exploring how the Success Story of Tarlatamab has Changed the Face of T-Cell Engagers: Clinical Development & Learnings
Time: 9:00 am
day: Day 1
Details:
- Tracing the clinical development of tarlatamab from preclinical rationale to recent trial outcomes in small cell lung cancer
- Evaluating efficacy, safety, and resistance mechanisms observed in clinical studies, with a focus on cytokine release syndrome and T-cell exhaustion
- Identifying key learnings from tarlatamab’s development to inform next-generation T-cell engagers, including target selection, dosing strategies, and combination approaches
